Another 745,000 Americans filed new unemployment claims for week ended Feb. 27

The results were close to the 750,000 expected

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

75.48-5.15 (-6.39%)

At close: 4:00PM EST

75.48 0.00 (0.00%)
Pre-Market: 8:00AM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	80.63
Open	80.61
Bid	75.03 x 900
Ask	77.50 x 1100
Day's Range	75.17 - 80.97
52 Week Range	19.51 - 92.60
Volume	843,099
Avg. Volume	882,005

Market Cap	7.834B
Beta (5Y Monthly)	1.39
PE Ratio (TTM)	N/A
EPS (TTM)	-1.00
Earnings Date	May 05, 2021 - May 10, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	92.42

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
- Xentria Announces Submission of an Investigational New Drug (IND) Application for XTMAB-16 in the Treatment of Sarcoidosis
  Business Wire
- FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
  Business Wire
Insider Monkey
Is Arrowhead Pharmaceuticals (ARWR) Stock a Buy For 2021?
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Health Care Fund returned 17.1% (institutional shares). In comparison, the benchmark S&P 500 Index was up 12.15%, while the Russell 3000 Health Care Index was up 10.08%. You should […]
Simply Wall St.
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Popular Amongst Institutions?
A look at the shareholders of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.